Catalyst

Slingshot members are tracking this event:

Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AERI

100%

Additional Information

Additional Relevant Details Aerie Pharmaceuticals announced the completion of patient enrollment in Rocket 4, the Company's Phase 3 clinical trial for RhopressaTM (netarsudil ophthalmic solution) 0.02% intended to satisfy filing requirements in Europe. RhopressaTM is a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 4 achieved total enrollment of approximately 700 patients and is a two-arm 90-day efficacy study, comparing once-daily RhopressaTM for non-inferiority to twice-daily timolol. The range for the primary endpoint mirrors Aerie's successful Rocket 2 trial, including patients with baseline IOPs ranging from above 20 mmHg (millimeters of mercury) to below 25 mmHg. Rocket 4 also includes a secondary endpoint range of baseline IOPs from above 20 mmHg to below 27 mmHg, and additionally a secondary endpoint timeframe of six months.
http://investors.aer...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rhopressa, Netarsudil Ophthalmic Solution, Rocket 4 Phase 3